- ROUNDTABLE: Pharmacy’s future in sync with technology
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- Lipitor may be the first statin to switch to OTC
- Senate passes Drug Quality and Security Act
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
THOUSAND OAKS, Calif. — Amgen will get rights to a drug for cardiovascular disease approved in the European Union under a new deal with French drug maker Servier, the two companies said Tuesday.
The drug, Procoralan (ivabradine) is used to threat chronic heart failure and stable angina in patients with elevated heart rates, and Amgen will also have an exclusive option to develop and commercialize an experimental Servier drug, S38844, for cardiovascular disease in the United States. That drug is currently in mid-stage clinical trials. The deal includes a $50 million upfront payment from Amgen plus future milestone and royalty payments.
"A critical unmet medical need remains for patients who don't respond adequately to current available therapies for heart failure and angina," Amgen EVP research and development Sean Harper said.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.